Alnylam Pharmaceuticals | Des Atouts



Assets Changement Date
Acadia Pharmaceuticals USD 1.19B 210.89M 2024-12
Agios Pharmaceuticals USD 1.66B 128.6M 2024-12
Alnylam Pharmaceuticals USD 4.24B 34.94M 2024-12
Amgen USD 91.84B 956M 2024-12
Arrowhead Research USD 1.01B 126.11M 2024-12
BioMarin Pharmaceutical USD 6.99B 137.74M 2024-12
Incyte USD 5.44B 431.89M 2024-12
Ionis Pharmaceuticals USD 3B 77.42M 2024-12
Moderna USD 14.14B 1.66B 2024-12
Neurocrine Biosciences USD 3.72B 183.7M 2024-12
Novartis USD 102.25B 1.28B 2024-12
PTC Therapeutics USD 1.71B 137.21M 2024-12
Regeneron Pharmaceuticals USD 37.76B 317.5M 2024-12
Sanofi 129.76B 3.29B 2024-06
Sarepta Therapeutics USD 3.96B 363.24M 2024-12
Takeda JPY 15.11T 533.85B 2024-12
Tectonic Therapeutic USD 168.72M 25.19M 2024-09
Ultragenyx Pharmaceutical USD 1.5B 34.91M 2024-12
Vertex Pharmaceuticals USD 22.53B 293M 2024-12
Xencor USD 951.94M 31.69M 2024-12



Alnylam Pharmaceuticals Des Atouts - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Mar 2025.